Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17814
Title: A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.
Authors: Chao, Michael;Spencer, Sandra;Guerrieri, Mario;Ding, Wei;Goharian, Mehran;Ho, Huong;Ng, Michael;Healey, Danielle;Tan, Alwin;Cham, Chee;Joon, Daryl Lim;Lawrentschuk, Nathan L ;Travis, Douglas;Sengupta, Shomik;Chan, Yee;Troy, Andrew;Pham, Trung;Clarke, David;Liodakis, Peter;Bolton, Damien
Affiliation: Genesis Cancer Care Victoria, Melbourne
The Bays Hospital, Mornington
Austin Health, Heidelberg, Victoria, Australia
The Valley Private Hospital, Mulgrave, Australia
Western Private Hospital, Footscray
Issue Date: Apr-2018
EDate: 2018-04-30
Citation: Journal of contemporary brachytherapy 2018; 10(2): 155-161
Abstract: To report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer. Between 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation. Follow-up was performed every 3 months for 12 months, then every 6 months over 4 years and included prostate specific antigen evaluation. The biochemical relapse-free survival (BRFS) was defined according to the Phoenix criteria. Acute and late toxicities were documented using the Common Terminology Criteria for Adverse Events version 4.0. The BRFS and OS estimates were calculated using Kaplan-Meier plots. Univariate and multivariate analyses were performed to evaluate outcomes by pre-treatment clinical prognostic factors and radiation dosimetry. The median follow-up of all patients was 5.45 years. The 5-year BRFS and OS rates were 95% and 96%, respectively. The BRFS rates for patients with Gleason score (GS) > 7 and GS ≤ 6 were 96% and 91% respectively (p = 0.06). On univariate analysis, T1 and T2 staging, risk-group classification, and prostate volumes had no impact on survival at 5 years (p > 0.1). Late grade 2 and 3 genitourinary (GU) toxicities were observed in 10% and 5% of patients respectively. Additionally, patients with prior TURP had a greater incidence of late grade 2 or 3 urinary retention (p = 0.001). There were 14 deaths in total; however, none were attributed to prostate cancer. LDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17814
DOI: 10.5114/jcb.2018.75600
ORCID: 0000-0001-8553-5618
0000-0002-5145-6783
PubMed URL: 29789764
ISSN: 1689-832X
Type: Journal Article
Review
Subjects: brachytherapy
prostatic neoplasms
transurethral resection of prostate
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.